This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 11.97% and 9.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
by Zacks Equity Research
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 6.54% and 43.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 6.04% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 11.90% and 9.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 0% and 26.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics (JANX) delivered earnings and revenue surprises of 65.63% and 1,078.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
by Zacks Equity Research
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
by Zacks Equity Research
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.